IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, has announced its participation in two upcoming investor conferences. The company's senior management will provide corporate updates and engage in one-on-one meetings at these events:
1. Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 4, 2024. CEO Mai-Britt Zocca, PhD, will participate in a fireside chat at 5:35 pm ET.
2. H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9, 2024. CFO Amy Sullivan will present at 10:30 am ET.
Webcasts of both presentations will be available on IO Biotech's website for 90 days following the events.
IO Biotech (Nasdaq: IOBT), un'azienda biofarmaceutica in fase clinica che sviluppa nuovi vaccini terapeutici antitumorali immunomodulanti, ha annunciato la sua partecipazione a due prossime conferenze per investitori. La direzione aziendale fornirà aggiornamenti aziendali e parteciperà a incontri individuali durante questi eventi:
1. 22° Convegno Annuale di Sanità Globale di Morgan Stanley a New York il 4 settembre 2024. Il CEO Mai-Britt Zocca, PhD, parteciperà a una chiacchierata informale alle 17:35 ET.
2. 26° Convegno Annuale di Investimenti Globali di H.C. Wainwright a New York il 9 settembre 2024. Il CFO Amy Sullivan presenterà alle 10:30 ET.
I webcast di entrambe le presentazioni saranno disponibili sul sito web di IO Biotech per 90 giorni dopo gli eventi.
IO Biotech (Nasdaq: IOBT), una empresa biofarmacéutica en etapa clínica que desarrolla nuevas vacunas terapéuticas contra el cáncer que modulan el sistema inmunológico, ha anunciado su participación en dos próximas conferencias para inversores. La alta dirección de la empresa proporcionará actualizaciones corporativas y participará en reuniones uno a uno en estos eventos:
1. 22ª Conferencia Anual Global de Salud de Morgan Stanley en Nueva York el 4 de septiembre de 2024. La CEO Mai-Britt Zocca, PhD, participará en una charla informal a las 5:35 p. m. ET.
2. 26ª Conferencia Anual Global de Inversiones de H.C. Wainwright en Nueva York el 9 de septiembre de 2024. La CFO Amy Sullivan presentará a las 10:30 a. m. ET.
Las grabaciones de ambas presentaciones estarán disponibles en el sitio web de IO Biotech durante 90 días después de los eventos.
IO Biotech (Nasdaq: IOBT), 면역 조절 요법 암 백신을 개발하는 임상 단계의 생명공학 회사가 두 개의 다가오는 투자자 회의에 참여한다고 발표했습니다. 기업의 고위 경영진은 이러한 이벤트에서 기업 업데이트를 제공하고 일대일 미팅에 참여할 것입니다:
1. 모건 스탠리 제22회 연례 글로벌 의료 회의가 2024년 9월 4일 뉴욕에서 열립니다. CEO 마이-브리트 조카, PhD,가 오후 5시 35분 ET에 화상 대화에 참여할 예정입니다.
2. H.C. 웨인라이트 제26회 연례 글로벌 투자 회의가 2024년 9월 9일 뉴욕에서 개최됩니다. CFO 에이미 설리반이 오전 10시 30분 ET에 발표할 예정입니다.
두 발표의 웹캐스트는 이벤트 후 90일 동안 IO Biotech의 웹사이트에서 사용할 수 있습니다.
IO Biotech (Nasdaq: IOBT), une société biopharmaceutique en phase clinique développant de nouveaux vaccins thérapeutiques anticancéreux modulateurs du système immunitaire, a annoncé sa participation à deux prochaines conférences pour investisseurs. La direction de l'entreprise fournira des mises à jour sur l'entreprise et participera à des réunions en tête-à-tête lors de ces événements :
1. 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley à New York le 4 septembre 2024. Le PDG Mai-Britt Zocca, PhD, participera à une discussion informelle à 17h35 ET.
2. 26e Conférence Annuelle Mondiale sur les Investissements de H.C. Wainwright à New York le 9 septembre 2024. La CFO Amy Sullivan fera une présentation à 10h30 ET.
Les webcasts des deux présentations seront disponibles sur le site Web d’IO Biotech pendant 90 jours après les événements.
IO Biotech (Nasdaq: IOBT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das neuartige, immunmodulierende therapeutische Krebsimpfstoffe entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das obere Management des Unternehmens wird Unternehmensaktualisierungen bereitstellen und individuelle Treffen bei diesen Veranstaltungen führen:
1. 22. Jahrestagung zur globalen Gesundheitsversorgung von Morgan Stanley in New York am 4. September 2024. CEO Mai-Britt Zocca, PhD, wird um 17:35 Uhr ET an einem Fireside-Chat teilnehmen.
2. 26. Jahrestagung für globale Investitionen von H.C. Wainwright in New York am 9. September 2024. CFO Amy Sullivan wird um 10:30 Uhr ET präsentieren.
Webcasts beider Präsentationen werden 90 Tage nach den Veranstaltungen auf der Website von IO Biotech verfügbar sein.
- None.
- None.
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will provide a corporate update and participate in one-on-one meetings at the following upcoming investor conferences:
Event: Morgan Stanley 22nd Annual Global Healthcare Conference
Location: New York, New York
Fireside Chat Date & Time: Wednesday, September 4, 2024 at 5:35 pm ET
Presenter: Mai-Britt Zocca, PhD, CEO
Webcast Link: Here
Event: H.C. Wainwright 26th Annual Global Investment Conference
Location: New York, New York
Presentation Time: Monday, September 9, 2024 at 10:30 am ET
Presenter: Amy Sullivan, CFO
Webcast Link: Here
A webcast replay of the presentations will be available on IO Biotech’s website at www.iobiotech.com for 90 days following the presentation.
About IO102-IO103
IO102-IO103 is an investigational off-the-shelf therapeutic cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase (IDO) positive and programmed death-ligand 1 (PD-L1) positive cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating IO102-IO103 in combination with pembrolizumab as first line treatment in patients with solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating IO102-IO103 in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors.
The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target the immunosuppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, IO102-IO103, in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with pembrolizumab, has been granted a breakthrough therapy designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing of the interim and primary analyses of the company’s Phase 3 trial, current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Contact:
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com
Media
Julie Funesti
Salutem
917-498-1967
Julie.Funesti@salutemcomms.com
FAQ
When is IO Biotech (IOBT) presenting at the Morgan Stanley Global Healthcare Conference?
Who will be presenting for IO Biotech (IOBT) at the H.C. Wainwright Global Investment Conference?
How long will the webcast replays of IO Biotech's (IOBT) presentations be available?
What type of company is IO Biotech (IOBT)?
